Research Paper Volume 15, Issue 24 pp 14996—15024
ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network
Figure 11. Constructing a nomogram for prognosis prediction. (A) The predicted 3-, 5- and 7-year survival rates of patients with BC are based on the prognostic nomogram. (B–D) C-index showed the concordances between predicted and observed 3-, 5- and 7-year survival rates based on the nomogram after bias corrections.